High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma.
- Author:
Sang Yun HA
1
;
Dae Hyun SONG
;
Jae Jun LEE
;
Hyun Woo LEE
;
Soo Youn CHO
;
Cheol Keun PARK
Author Information
- Publication Type:Original Article
- Keywords: AKR1B10; Carcinoma, hepatocellular; Survival
- MeSH: Adolescent; Adult; Aged; Aldehyde Reductase/*metabolism; Carcinoma, Hepatocellular/*metabolism/surgery; Disease-Free Survival; Female; Hepatectomy; Humans; Immunohistochemistry; Liver Neoplasms/*metabolism/surgery; Male; Middle Aged; Prognosis; Tumor Markers, Biological/*metabolism; Young Adult
- From:Gut and Liver 2014;8(6):648-654
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Upregulation of aldo-keto reductase 1B10 (AKR1B10) through the mitogenic activator protein-1 signaling pathway might promote hepatocarcinogenesis and tumor progression. The goal of this study was to evaluate the prognostic significance of AKR1B10 protein expression in patients with hepatocellular carcinoma after surgery. METHODS: A tissue microarray was used to detect the expression level of AKR1B10 protein in tumors from 255 patients with hepatocellular carcinoma who underwent curative hepatectomy. The impact of AKR1B10 expression on the survival of patients was analyzed. The median follow-up period was 119.8 months. RESULTS: High AKR1B10 protein expression was observed in 125 of the 255 patients with hepatocellular carcinoma (49.0%). High AKR1B10 expression was significantly associated with a lack of invasion of the major portal vein (p=0.022), a lack of intrahepatic metastasis (p=0.010), lower the American Joint Committee on Cancer T stage (p=0.016), lower the Barcelona Clinic Liver Cancer stage (p=0.006), and lower alpha-fetoprotein levels (p=0.020). High AKR1B10 expression was also correlated with a lack of early recurrence (p=0.022). Multivariate analyses of survival revealed that intrahepatic metastases and lower albumin levels were independent predictors of both shorter recurrence-free survival and shorter disease-specific survival. High AKR1B10 expression was an independent predictor of both longer recurrence-free survival (p=0.024) and longer disease-specific survival (p=0.046). CONCLUSIONS: High AKR1B10 protein expression might be useful as a marker of a favorable prognosis in patients with hepatocellular carcinoma after curative hepatectomy.
